NCT05978063 — Pruritus trial site landscape

Public-registry site landscape for NCT05978063, “Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica”, a Pruritus study sponsored by Cara Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05978063 (registry record)
Study title	Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
Official title	A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica
Sponsor	Cara Therapeutics, Inc.
Condition(s)	Pruritus; Notalgia Paresthetica
Phase	PHASE2 / PHASE3
Listed sites	58
Site countries	United States, Canada, Germany, Poland, Spain

Patient-friendly overview of this study: eichor.com/study/NCT05978063.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05978063 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →